GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?

25th October 2017 Uncategorised 0

GlaxoSmithKline said Wednesday that it’s looking hard at Pfizer’s up-for-sale OTC unit—but that was bad news to analysts worried about the fate of the company’s dividend.

More: GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend?
Source: fierce